Single-center, Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of RG1662 Given BID Over 28 Days, and in Addition, the Excretion and Metabolism of [13C]-Labelled IV Microdoses and an Oral [14C]-Labelled Dose of RG1662 in Healthy Male Volunteers
Latest Information Update: 13 Jun 2016
Price :
$35 *
At a glance
- Drugs Basmisanil (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Roche
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2012 New trial record